Arnold & Porter Advises Pharmacosmos A/S in its Merger Agreement with G1 Therapeutics Inc.

Arnold & Porter represented Pharmacosmos A/S, a leader in the development of innovative treatments for iron deficiency, in a definitive merger agreement under which Pharmacosmos will acquire G1 Therapeutics Inc., a North Carolina based commercial-stage oncology company focused on delivering next-generation therapies that improve the lives of those affected by cancer, for a total equity value of approximately $405 million.

G1's Cosela is the only product approved by the U.S. Food and Drug Administration to decrease the incidence of chemotherapy-induced myelosuppression in extensive-stage small-cell lung cancer patients.

The deal will maximize availability of Cosela for patients and expands Pharmacosmos’ ability to work with oncologists in the U.S.

The parties expect the deal to close late in the third quarter of 2024.

The Arnold & Porter team was led by partners Lowell Dashefsky, co-head of the firm's Private Equity and Life Sciences Transactions practices, and Michael Penney, a partner in the M&A and capital markets practices, and included associate Claire Frost.